Answers are grounded in this paper and cite their sources.
To report real-world experience on the use of anifrolumab (ANI) in refractory systemic lupus erythematosus (SLE).
No takes yet. Share an insight, caveat, or question.
Tani et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: